In short
This article discusses clinical trials investigating the use of Dexamethasone Acetate Ph. Eur., specifically the drug OXU-001, for treating Diabetic Macular Edema (DME). The trials aim to evaluate the safety, tolerability, efficacy, and durability of suprachoroidal OXU-001 compared to intravitreal dexamethasone implants in patients with DME. The study utilizes an innovative drug delivery method using the Oxulumis® Illuminated Microcatheterization Device for administering OXU-001 to the suprachoroidal space.
At a glance
- Study Drug
- OXU-001 (Dexamethasone Acetate Ph. Eur.)
- Condition Studied
- Diabetic Macular Edema (DME)
- Study Design
- Multi-center, randomized, parallel-group, Phase 2 trial
- Treatment Method
- Suprachoroidal injection using Oxulumis® Illuminated Microcatheterization Device
- Comparison
- OXU-001 vs. Intravitreal Ozurdex® (dexamethasone implant)
- Primary Endpoints
- Frequency and severity of ocular and systemic adverse events, device adverse effects
- Secondary Endpoints
- Time to follow-on treatment, changes in visual acuity and central subfield thickness, quality of life measures
- Study Duration
- Up to 58 weeks per participant
What is Dexamethasone Acetate?
Dexamethasone Acetate PH. EUR., also known as OXU-001, is a corticosteroid medication being studied for the treatment of Diabetic Macular Edema (DME). Corticosteroids are powerful anti-inflammatory drugs that can help reduce swelling and inflammation in various parts of the body, including the eye.
What is Diabetic Macular Edema?
Diabetic Macular Edema (DME) is a complication of diabetes that affects the eyes. It occurs when fluid builds up in the macula, the central part of the retina responsible for sharp, detailed vision. This fluid accumulation causes the macula to swell, leading to blurred or distorted central vision.
How is OXU-001 Used?
OXU-001 is administered through a novel approach called suprachoroidal injection. This method uses a special device called the Oxulumis® Illuminated Microcatheterization Device. Here's how it works:
- A tiny needle is inserted into the white part of the eye (sclera).
- A microcatheter is deployed into the suprachoroidal space, which is a layer between the white of the eye and the retina.
- The device has a light that confirms correct placement of the microcatheter.
- Once confirmed, OXU-001 is injected into this space.
This method allows for targeted delivery of the medication to the affected area of the eye.
Potential Benefits
Researchers are studying OXU-001 to determine its potential benefits for patients with DME. Some of the hoped-for outcomes include:
- Improved vision, measured by the ability to read more letters on an eye chart
- Reduced swelling in the macula
- Longer-lasting effects compared to current treatments
- Improved quality of life related to vision
Who Can Receive OXU-001?
The ongoing clinical trial has specific criteria for who can participate. Generally, candidates should:
- Be at least 18 years old
- Have been diagnosed with Type 1 or Type 2 diabetes
- Have DME affecting the center of vision
- Have certain levels of vision and retinal thickness as measured by special tests
There are also many factors that might exclude someone from receiving OXU-001, such as certain eye conditions, recent eye surgeries, or uncontrolled diabetes.
Safety Considerations
As with any medical treatment, there are potential risks and side effects. The ongoing study is closely monitoring:
- Any adverse events in the eye or elsewhere in the body
- Changes in eye pressure
- Any issues related to the injection procedure
It's important to note that OXU-001 is still being studied, and not all potential side effects may be known at this time.
Ongoing Research
OXU-001 is currently being studied in a Phase 2 clinical trial. This trial is comparing different doses of OXU-001 to an existing treatment called Ozurdex® (another form of dexamethasone). The study aims to evaluate:
- The safety and tolerability of OXU-001
- How long the effects of the treatment last
- How well it improves vision and reduces macular swelling
- How it impacts patients' quality of life
This research is crucial in determining whether OXU-001 could become a new treatment option for people with Diabetic Macular Edema in the future.